Application of Treg cell and sIL-2R in predicting rejection of liver transplantation patient
By detecting the number of CD3+CD4+CD25hiCD127-Treg cells and serum sIL-2R concentration in the peripheral blood of patients with liver transplantation, a prediction system was constructed, which solved the problem of failure to effectively predict postoperative rejection reactions in patients with liver transplantation in the prior art, and achieved It has higher prediction accuracy and clinical application value.
Patent Information
- Application Number
- CN202411039556.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-31
- Publication Date
- 2024-11-19
AI Technical Summary
The prior art has failed to effectively predict whether liver transplant patients undergo rejection after surgery, and lacks rapid and simple clinical practical indicators.
CD3+CD4+CD25hiCD127-Treg cells combined with sIL-2R as biomarkers were used to detect the number of Treg cells and serum sIL-2R in peripheral blood by flow cytometry and electrochemiluminescence immunoassay to construct a prediction system to predict liver The occurrence of postoperative rejection reactions in transplant patients.
Through combined indicators, the prediction accuracy of rejection reactions is improved. The area under the ROC curve (AUC) is 0.737, providing a fast and simple detection method and has good clinical application value.
Smart Images

Figure CN118983094A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to an application of Treg cells combined with sIL-2R in predicting rejection reaction in liver transplant patients, belonging to the technical field of biomedical detection. Background Art
[0002] The surgical process of allogeneic orthotopic liver transplantation and the use of postoperative immunosuppressive drugs can activate and reshape the immune system status of liver transplant patients. Various innate and adaptive immune cells involved in this immune remodeling process, such as T lymphocytes, B lymphocytes, monocytes and natural killer cells, play different immune functions. Maintaining the immune balance homeostasis between immune effector cells and immune regulatory cells is one of the keys to prolong graft function and graft survival. The gene expression levels and expression patterns of immune effector cells and immune regulatory cells (SMAD3, FOXP3, IL2RB, KLRB1, SLAMF7-1, SLAMF7-2, ZBTB21-1, ZBTB21-2 and CX3CR1-2), cell phenotypic marker molecules (HLA-DR, CD36, CD45RA, CD45RO, TLR4, Tight, LAG3, Tim3 and CTLA4, etc.) and changes in immune function and signaling pathways in different microenvironments have been proven to be able to predict the possible mechanism of immune tolerance or the risk of transplant-related rejection.
[0003] Immunosuppressive drugs used after solid organ transplantation exert immunosuppressive effects through different pharmacological actions, including glucocorticoids, antimetabolites such as mycophenolic acid and azathioprine, calcineurin inhibitors (CNIs) such as cyclosporine and tacrolimus that activate lymphocytes by blocking IL-2, mammalian target of rapamycin inhibitors (mTOR inhibitors) such as rapamycin and sirolimus, and anti-IL2R (CD25) monoclonal antibody basiliximab. At the same time, because the liver is known as an immune-privileged organ, studies have shown that up to 20% of patients can achieve immune tolerance about 5-10 years after liver transplantation. Therefore, one of the clinical goals is to try to establish immune tolerance and reduce the risk of rejection reactions to prolong graft function and improve the patient's quality of life.
[0004] Therefore, it is of great clinical significance to predict whether rejection or immune tolerance will occur through the overall picture of immune function changes in patients after liver transplantation, and to establish an effective prediction model or an indicator with strong clinical practicality. Regulatory T cells (Tregs) are a type of T lymphocyte subset that is recognized to have negative immune regulatory functions and can maintain immune balance. Studies have reported that Tregs play an important role in inducing immune tolerance in solid organ transplantation. Tregs characterized by downregulation of pro-inflammatory gene expression are significantly enriched in the liver tissue of patients with immune tolerance after liver transplantation. Tregs exert immunosuppressive functions through different mechanisms of action. They secrete anti-inflammatory cell molecules (IL-10 and TGF-β), express inhibitory co-stimulatory molecules CTLA4 and LAG3 to inhibit the function of antigen-presenting cells (APC), and release granzymes and perforins to cause effector cell lysis. Tregs can consume key growth factors from the immune microenvironment to prevent effector cells from obtaining energy or causing them to lose energy or apoptosis. In addition, Tregs can absorb and consume essential amino acids and express in vitro enzymes CD39 and CD73, which destroy the key process of effector cell energy metabolism, resulting in monocytes being unable to obtain energy and inducing their differentiation into immunosuppressive macrophages (M2 type) and inhibiting the function of Th17, thereby playing a role in maintaining immune homeostasis and inducing immune tolerance. This is also the theoretical basis for polyclonal regulatory T cell infusion experiments. Currently, there are many clinical trials involving the infusion of in vitro expanded commercial Tregs to establish immune tolerance in patients with solid organ transplants such as kidney and liver transplants.
[0005] However, there is no research on the expression of CD3 + CD4 + CD25 hi CD127 - There are reports on Treg cells combined with sIL-2R as predictors of rejection in liver transplant patients. Summary of the invention
[0006] The purpose of the present invention is: the present invention aims to provide an application of Treg cells combined with sIL-2R in predicting rejection reactions in liver transplant patients.
[0007] In order to achieve the above object, the present invention provides a CD3 + CD4 + CD25 hi CD127 - The application of Treg cells combined with sIL-2R as biomarkers in the preparation of products for predicting rejection reactions in liver transplant patients.
[0008] Preferably, the product comprises a prediction system or a detection kit.
[0009] The present invention also provides an application of a detection reagent in the preparation of a kit for predicting rejection in liver transplant patients, wherein the detection reagent at least comprises: a detection reagent for detecting CD3 + CD4 + CD25 hi CD127 - A reagent for detecting Treg cells, and a reagent for detecting the concentration of sIL-2R in the serum of a subject.
[0010] Preferably, the detection of CD3 + CD4 + CD25 hi CD127 - The reagent for Treg cells is a reagent or kit used for flow cytometry detection; for example, an immune cell counting tube from USA BD Bioscience is used to perform absolute counting of immune cells.
[0011] Preferably, the reagent for detecting the concentration of sIL-2R in the serum of the subject is a reagent or kit used for electrochemiluminescence immunoassay; for example, a commercial kit (Siemens, Germany) is used to detect the concentration of sIL-2R in serum.
[0012] The present invention also provides a combined CD3 + CD4 + CD25 hi CD127 - A system for predicting rejection in liver transplant patients using Treg cells and sIL-2R, the system comprising a sample collection device, a separation device, a detection device and a prognosis determination device;
[0013] Wherein, the sample collection device is configured as a device for collecting peripheral blood samples from a subject, and the subject is a liver transplant patient;
[0014] The separation device is configured as a device for separating peripheral blood mononuclear cells from the peripheral blood sample;
[0015] The detection device includes a method capable of detecting CD3 + CD4 + CD25 hi CD127 - means of Treg cell numbers and serum sIL-2R concentrations;
[0016] The prediction device is configured to include a memory and a processor, wherein the memory stores a computer program, and the processor is configured to execute the computer program stored in the memory to achieve: according to the CD3 + CD4 + CD25 hi CD127 - Changes in the number of Treg cells and the concentration of sIL-2R can predict whether the subjects will experience liver transplant rejection.
[0017] By analyzing the single-cell sequencing data of liver transplant patients and other patients with liver diseases, the present invention found that IL-2RA (CD25) was mainly expressed on Treg cells; and it was observed that the level of sIL-2R in the peripheral serum of patients after liver transplantation gradually increased. Since IL-2R is found in the peripheral blood in the soluble form of IL-2R (sIL-2R / CD25), and during the immune activation process, IL-2R can fall off the activated immune cell membrane and enter the blood. The free sIL-2R competitively binds to IL-2 to reduce the bioavailability of IL-2; therefore, it is speculated that this phenomenon is conducive to inducing tolerance rather than maintaining immune activation reactions. The analysis results indicate that the level of sIL-2R in the peripheral serum of patients with rejection reactions after liver transplantation is on the rise. Combined with the level of CD3 in the peripheral blood of patients in the early stage after liver transplantation, + CD4 + CD25 hi CD127 - The number of Tregs decreased sharply, and it was speculated that the rapid increase of sIL-2R in peripheral blood may be mainly due to CD3 + CD4 + CD25 hi CD127 - Rapid shedding of CD25 on the surface of Treg cells into peripheral serum.
[0018] Compared with the prior art, the present invention has the following beneficial effects:
[0019] The present invention converts CD3 + CD4 + CD25 hi CD127 - The decrease in the number of Treg cells combined with the increase in sIL-2R content are used as indicators for predicting postoperative rejection reactions in liver transplant patients, and the area under the ROC curve (AUC) is 0.737. This combined indicator shows better predictive value than a single indicator. The present invention provides a rapid and simple detection method for whether postoperative rejection reactions occur in liver transplant patients, and has good clinical application value. BRIEF DESCRIPTION OF THE DRAWINGS
[0020] Figure 1 The percentages and absolute counts of various lymphocyte subsets in peripheral blood before and after liver transplantation; *: P<0.05; **: P<0.01; ***: P<0.001;
[0021] Figure 2 The expression levels of various cytokines in the peripheral blood of patients before and after liver transplantation; *: P<0.05; **: P<0.01; ***: P<0.001;
[0022] Figure 3 Effects of BXM on sIL-2R levels and Treg cell numbers in LT patients: A. Absolute counts of Treg and sIL-2R concentrations in LT patients without BXM injection; B. Comparison of Treg and sIL-2R in LT patients with and without BXM; *: P < 0.05; **: P < 0.01; ***: P < 0.001;
[0023] Figure 4 The correlation between IL-2R expression profile and Treg cells in LT patients: A. Single-cell UMAP showed that Treg cells mainly expressed IL-2RA; B. Flow cytometry results showed that the expression of IL-2R in Treg cells was significantly higher than that in other CD4-positive T cells; C. The correlation between sIL-2R and various T lymphocyte subsets; *: P<0.05; **: P<0.01; ***: P<0.001;
[0024] Figure 5 To present the relationship between serum sIL-2R reduction and prognosis in liver transplant patients: A. Changes in mean fluorescence intensity of CD25 on Treg cells before and after liver transplantation, and the difference in mean fluorescence intensity of CD25 between rejection patients and immune-tolerant patients; B. Differences in peripheral blood Treg cells and sIL-2R between rejection patients and immune-tolerant patients on days 5 and 20 after transplantation; C. Evaluation of diagnostic efficacy of rejection after liver transplantation using Treg cells and sIL-2R; *: P<0.05; **: P<0.01; ***: P<0.001. DETAILED DESCRIPTION
[0025] In order to make the present invention more clearly understood, preferred embodiments are described in detail below with reference to the accompanying drawings.
[0026] The experimental methods in the following examples without specifying specific conditions were carried out according to conventional methods and conditions, or selected according to the product instructions; the materials, reagents, etc. used were conventional commercially available products unless otherwise specified.
[0027] Example 1
[0028] 1. Sample Collection and Experimental Methods
[0029] 1) Sample inclusion and exclusion criteria
[0030] A total of 81 patients underwent allogeneic orthotopic liver transplantation in the Department of Liver Oncology Surgery, Zhongshan Hospital Affiliated to Fudan University from July to November 2021 and September to October 2023. The immune induction regimen of the enrolled patients was divided into the basiliximab group and the non-basiliximab group. Among them, 61 patients were given 20 mg basiliximab (BXM) (Novartis Pharmastein AG, Switzerland) once on day 0 and day 4 after liver transplantation; the other 20 patients did not receive BXM injection. After surgery, all liver transplant patients received triple immunosuppressive therapy: methylprednisolone, mycophenolate mofetil (MMF), and tacrolimus (TAC). The exclusion criteria for this study were as follows: (1) patients with a history of other tumors or other major systemic diseases, such as severe cardiovascular, pulmonary, neurological or psychiatric diseases; (2) patients who had undergone surgical resection or chemotherapy before admission.
[0031] 2) Collect serum samples from patients before and after liver transplantation at certain time points
[0032] The observation period of this study started from liver transplantation to the occurrence of acute rejection (AR), death, or withdrawal of authorization and consent by the patient. AR was defined as clinical suspicion (aspartate aminotransferase or alanine aminotransferase more than 2 times the upper limit of baseline) and confirmed by biopsy pathology.
[0033] 3) Bioinformatics data collection
[0034] Single-cell RNA sequencing data maps of liver transplant patients and other liver disease patients (GSE200340, GSE162616, and GSE218121) were obtained from NCBI Geo DataSets (https: / / www.ncbi.nlm.nih.gov / gds / );
[0035] 4) Flow cytometry to detect the absolute count of immune cells in the peripheral blood of patients before and after liver transplantation
[0036] Peripheral blood mononuclear cells (PBMCs) were isolated from whole blood using Ficoll (GE Healthcare Bio sciences AB, Sweden) and stained for surface markers for 15 minutes at room temperature. The cells were then fixed and permeabilized with a transcription factor buffer set (BD Bioscience, USA) and stained for intracellular markers or Foxp3. The stained PBMCs were detected using Canto II (BD Bioscience, USA) and analyzed using Flowjo 10.6.2 (BD Bioscience, USA); and the absolute count of immune cells was performed using an immune cell counter tube from BD Bioscience, USA.
[0037] 5) Detection of cytokine profiles in peripheral blood serum of patients before and after liver transplantation
[0038] IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12, IL-17A, IL-17F, IL-22, TNF-α, TNF-β, and IFN-γ were detected by flow cytometry CBA cytokine kit (QuantoBio, China), and soluble interleukin-2 receptor (sIL-2R) was detected by electrochemiluminescence immunoassay using a commercial kit (Siemens, Germany).
[0039] 6) Statistical analysis
[0040] Statistical analysis was performed using SPSS 19.0 software (IBM, Chicago, USA). Experimental values were expressed as Mean ± SD. The Student t test, chi-square test, or Fisher test were used to compare the differences between the groups as appropriate. The Log-rank test was used to analyze the differences between the groups. P < 0.05 was considered statistically significant.
[0041] 2. Experimental Results
[0042] 1) Changes of immune cells in patients after liver transplantation
[0043] Changes of various immune cells in peripheral blood of patients on the 5th and 20th days before and after BXM injection. Figure 1As shown in the data, after the patients received BXM and immunosuppressive treatment, the percentage of B cells increased rapidly from (18.08±11.73%) to (33.02±19.84%), but this phenomenon may be mainly due to the rapid decline of T lymphocytes. In fact, there was no significant difference in the absolute counts of B lymphocytes before treatment (124.90±106.09 cells / μL) and after treatment (day 5: 160.61±152.18 cells / μL and day 20: 144.19±127.03 cells / μL). In addition, after taking immunosuppressive drugs, various immune cells of liver transplant patients were first significantly downregulated and gradually returned to the pre-treatment level on the 20th day; for example, the absolute count of peripheral blood T lymphocytes of liver transplant patients decreased from 509.27±403.53 cells / μL to 261.23±199.40 cells / μL, and increased to 435.89±252.58 cells / μL within 20 days; the number of Th cells decreased from 288.25±224.08 cells / μL to 148.89±123.59 cells / μL, and then increased again to 239.52±161.14 cells / μL. The number of T lymphocytes decreased from 193.56±187.80 cells / μL to 98.29±82.17 cells / μL, and then rebounded to 180.13±119.56 cells / μL. At the same time, the patient's peripheral blood NK cells dropped from 111.56±94.45 cells / μL to 51.78±51.00 cells / μL, and then rebounded to 88.53±81.96 cells / μL. + CD4 + CD25 hi CD127 dim The absolute number of Treg cells decreased from 62.33±52.45 cells / μL to 22.29±17.13 cells / μL, and then rebounded to 34.63±23.21 cells / uL, indicating that the CD3 + CD4 + CD25 hi CD127 - The Treg cell count was still significantly lower than the preoperative level ( Figure 1 ).
[0044] 2) Changes of cytokines in patients after liver transplantation
[0045] The cytokine levels of liver transplant patients before liver transplantation and on the 5th and 20th days after liver transplantation were analyzed. The types of cytokines analyzed included: sIL-2R, IL-1b, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12, IL-17A, IL-17F, IL-22, TNF-α, TNF-β, IFN-γ and IL-2. The results showed that the sIL-2R level increased significantly, rising to 1858.75±1601.91U / ml on the 20th day after treatment, which was higher than the 533.77±371.41U / ml before surgery and 820.15±365.84U / ml on the 5th day after surgery. The serum IL-17A level reached 11.88±10.80pg / ml on the 5th day after surgery, and the peripheral blood IL-17A level dropped significantly to 1.50±0.97pg / ml on the 20th day. In addition, IL-6 and IL-10 levels increased on day 5 after surgery and then returned to preoperative levels on day 20, with no significant statistical differences observed between the two time points. It is worth noting that there were no significant differences in other cytokines before and after surgery ( Figure 2 ).
[0046] 3) Effect of BXM on sIL-2R level and CD3 in liver transplant patients + CD4 + CD25 hi CD127 - Effect of Treg cell number
[0047] Serum sIL-2R concentrations and absolute counts of Treg cells were evaluated in 20 liver transplant patients who did not receive BXM. + CD4 + CD25 hi CD127 - Treg cell counts decreased, but this decrease was not statistically significant compared with preoperative levels. + CD4 + CD25 hi CD127 - Treg cell counts returned to preoperative levels; at the same time, the serum sIL-2R concentration in this group of patients gradually increased after surgery, from the initial 448.30±302.17pg / ml to 616.70±327.88pg / ml on the 5th day, and further increased to 1069.77±954.09pg / ml on the 20th day. However, compared with the level before liver transplantation, there was no statistical difference in the sIL-2R level on the 5th day ( Figure 3 A).
[0048] Therefore, we further compared the expression of sIL-2R and CD3 between patients who received BXM during liver transplantation and those who did not. + CD4 + CD25 hi CD127 - Whether there is a difference in Treg levels, the results showed that the CD3 + CD4 + CD25 hi CD127 - The absolute number of Treg cells was lower than that of patients who did not receive BXM. Although there was no significant difference between the two groups on day 20. In addition, sIL-2R analysis showed that compared with patients who did not receive BXM treatment, patients who received BXM treatment had significantly higher sIL-2R levels on days 5 and 20 after surgery, and the difference between the two groups was statistically significant ( Figure 3 B).
[0049] 4) IL-2R expression profile and CD3 in liver transplant patients + CD4 + CD25 hi CD127 - Correlation analysis of Treg cells
[0050] The single-cell sequencing data of peripheral blood samples from multiple liver transplant patients and other patients with liver diseases from the GEO database were analyzed. The expression profile of IL-2R in different cell populations was evaluated by dimensionality reduction and clustering techniques. The results clearly showed that IL-2RA (CD25) was expressed in CD3 + CD4 + CD25 hi CD127 - Dominant expression on Treg cells ( Figure 4 A). To confirm these observations at the protein level, we used flow cytometry to detect IL-2RA (CD25) on CD3 + CD4 + CD25 hi CD127 - The expression of Treg cells is significantly higher than that of other CD4 + T lymphocytes ( Figure 4 B) Therefore, soluble IL-2R in serum may be derived from CD3 + CD4 + CD25 hi CD127 -CD25 shed from the surface of Treg cells, and the correlation analysis between serum sIL-2R concentration and the absolute counts of various T lymphocyte subsets showed that CD3 + CD4 + CD25 hi CD127 - The number of Treg cells was significantly negatively correlated with the serum sIL-2R level (R=0.079; P=0.033) ( Figure 4 C).
[0051] 5) Correlation analysis between serum sIL-2R decrease and rejection in liver transplant patients
[0052] CD3 was detected in liver transplant patients before and after surgery at different time points + CD4 + CD25 hi CD127 - The expression of CD25 on the surface of Treg cells (i.e., mean fluorescence intensity, MFI) showed that in patients receiving BXM immune induction therapy, CD3 + CD4 + CD25 hi CD127 - The expression of CD25 on Treg cells was significantly reduced. In addition, the expression of CD3 + CD4 + CD25 hi CD127 - The expression of CD25 on Treg cells was significantly decreased, and the difference between the two groups was statistically significant ( Figure 5 A).
[0053] We evaluated the CD3 in peripheral blood of patients on days 5 and 20 after surgery (including samples from patients who received BXM immunotherapy and those who did not). + CD4 + CD25 hi CD127 - The number of Treg cells, serum sIL-2R concentration and the occurrence of rejection reactions were correlated. The results showed that the serum sIL-2R concentration of liver transplant patients with rejection reactions on the 5th day was significantly lower than that of patients without rejection reactions ( Figure 5 B). Using ROC analysis to evaluate the predictive power of these indicators, we found that the sIL-2R level on day 5 showed strong predictive power, with an area under the curve of 0.737 ( Figure 5 C).
[0054] The above description is only a preferred embodiment of the present invention and is not any formal or substantial limitation of the present invention. It should be pointed out that a person skilled in the art can make several improvements and supplements without departing from the present invention, and these improvements and supplements should also be regarded as the protection scope of the present invention.
Claims
1. CD3 + CD4 + CD25 hi CD127 - The application of Treg cells combined with sIL-2R as biomarkers in the preparation of products for predicting rejection reactions in liver transplant patients.
2. The use according to claim 1, characterized in that The product includes a prediction system or a detection kit.
3. Use of a detection reagent in the preparation of a kit for predicting rejection in liver transplant patients, characterized in that: The detection reagent at least includes: for detecting CD3 + CD4 + CD25 hi CD127 - A reagent for detecting Treg cells, and a reagent for detecting the concentration of sIL-2R in the serum of a subject.
4. The use according to claim 3, characterized in that The method for detecting CD3 in peripheral blood of a subject + CD4 + CD25 hi CD127 - The reagent for Treg cells is a reagent or a kit used for flow cytometry detection.
5. The use according to claim 3, characterized in that The reagent for detecting the concentration of sIL-2R in the serum of the subject is a reagent or a kit used for detection by electrochemiluminescence immunoassay.
6. A combined CD3 + CD4 + CD25 hi CD127 - The system of Treg cells and sIL-2R for predicting rejection in liver transplant patients is characterized in that: The system includes a sample collection device, a separation device, a detection device and a prognosis determination device; Wherein, the sample collection device is configured as a device for collecting peripheral blood samples from a subject, and the subject is a liver transplant patient; The separation device is configured as a device for separating peripheral blood mononuclear cells from the peripheral blood sample; The detection device includes a method capable of detecting CD3 + CD4 + CD25 hi CD127 - means of Treg cell numbers and serum sIL-2R concentrations; The prediction device is configured to include a memory and a processor, wherein the memory stores a computer program, and the processor is configured to execute the computer program stored in the memory to achieve: according to the CD3 + CD4 + CD25 hi CD127 - Changes in the number of Treg cells and the concentration of sIL-2R can predict whether the subjects will experience liver transplant rejection.
